IndexIQ Advisors’s United Therapeutics UTHR Stock Holding History

IndexIQ Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$72K	Buy	399 +220	+123%	+$41.9K	﹤0.01%	1112
2021 Q4	$39K	Buy	179 +9	+5%	+$1.77K	﹤0.01%	1128
2021 Q3	$31K	Sell	170 -11	-6%	-$2.17K	﹤0.01%	1128
2021 Q2	$32K	Sell	181 -3	-2%	-$571	﹤0.01%	1110
2021 Q1	$31K	Sell	184 -2,025	-92%	-$338K	﹤0.01%	1095
2020 Q4	$335K	Buy	2,209 +228	+12%	+$29.9K	0.01%	589
2020 Q3	$200K	Buy	1,981 +109	+6%	+$12K	0.01%	647
2020 Q2	$227K	Sell	1,872 -55	-3%	-$6.19K	0.01%	454
2020 Q1	$183K	Buy	+1,927	New	+$183K	0.01%	616

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

IndexIQ Advisors's UTHR Position: Q1 2022 in Review

IndexIQ Advisors increased its United Therapeutics (UTHR) stake by 123% in Q1 2022, buying an estimated $41.9K and bringing the position to 399 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #1112.

IndexIQ Advisors first reported a position in UTHR in Q1 2020 and has held it in 9 quarters since. The position peaked at $335K in Q4 2020. 428 funds tracked by Wall St. Rank hold UTHR as of Q1 2022.

IndexIQ Advisors held 399 shares of United Therapeutics worth $72K as of Q1 2022.
IndexIQ Advisors bought 220 United Therapeutics shares in Q1 2022, an estimated $41.9K.
United Therapeutics made up ﹤0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #1112 holding.
IndexIQ Advisors first reported a position in United Therapeutics in Q1 2020 and has held it in 9 quarters since.
IndexIQ Advisors's United Therapeutics position peaked at $335K in Q4 2020.
428 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.